ERBB2 and breast cancer: Lapatinib in combination with capecitabine was registered as a second-line treatment after failure of therapy containing anthracyclines, taxanes, and trastuzumab in patients with advanced, HER2-positive BC based on the pivotal NCT00078572 study.